DrugPatentWatch Database Preview
Drugs in Development Information for VTP-27999
» See Plans and Pricing
What is the development status for investigational drug VTP-27999?
VTP-27999 is an investigational drug.
There have been 17 clinical trials for VTP-27999.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 21st 2019.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Psoriasis, and Neovascularization, Pathologic. The leading clinical trial sponsors are Steba Biotech S.A., Vitae Pharmaceuticals, Inc., and STEBA France.
There are four US patents protecting this investigational drug and fifty-nine international patents.
Summary for VTP-27999
| US Patents | 4 |
| International Patents | 59 |
| US Patent Applications | 6 |
| WIPO Patent Applications | 3 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2019-01-21) |
| Vendors | 49 |
Recent Clinical Trials for VTP-27999
| Title | Sponsor | Phase |
|---|---|---|
| Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer | Steba Biotech S.A. | Phase 3 |
| Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate Cancer | International Drug Development Institute | Phase 4 |
| Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate Cancer | PrimeVigilance LTD | Phase 4 |
Clinical Trial Summary for VTP-27999
Top disease conditions for VTP-27999
Top clinical trial sponsors for VTP-27999
US Patents for VTP-27999
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| VTP-27999 | Start Trial | Piperidine renin inhibitors | Vitae Pharmaceuticals, Inc. (Fort Washington, PA) | Start Trial |
| VTP-27999 | Start Trial | Salts of methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-2-(methylamino)-3-((R)-tetrahydro-2H-p- yran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate | Vitae Pharmaceuticals, Inc. (Fort Washington, PA) | Start Trial |
| VTP-27999 | Start Trial | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | Vitae Pharmaceuticals, Inc. (Fort Washington, PA) | Start Trial |
| VTP-27999 | Start Trial | Piperidine renin inhibitors | Vitae Pharmaceuticals, Inc. (Fort Washington, PA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for VTP-27999
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| VTP-27999 | Argentina | 057890 | 2025-11-14 | Start Trial |
| VTP-27999 | Argentina | 062797 | 2025-11-14 | Start Trial |
| VTP-27999 | Austria | 520690 | 2025-11-14 | Start Trial |
| VTP-27999 | Austria | 538092 | 2025-11-14 | Start Trial |
| VTP-27999 | Australia | 2006325322 | 2025-11-14 | Start Trial |
| VTP-27999 | Australia | 2007297729 | 2025-11-14 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
